logo
Plus   Neg
Share
Email

FDA Approves Aimmune's (AIMT) Palforzia, Stock Up 17% In After-Hours

The FDA has approved Aimmune Therapeutics Inc.'s (AIMT) Palforzia for the treatment of peanut allergy in patients aged 4 through 17 years.

Up-dosing and maintenance may be continued in patients 4 years of age and older, and the drug is to be used in conjunction with a peanut-avoidant diet, the Company noted.

Palforzia is not only the first approved therapy for peanut allergy but is also the first approved therapy for any food allergy. It is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

AIMT closed Friday's trading at $31.05, down 2.91%. In after-hours, the stock was up 16.88% to $36.29.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. is planning to cut pays and furlough non-essential workers as the shut down of its vehicle production continues amid escalating coronavirus or Covid-19 cases. As per multiple reports citing an e-mail sent to all employees by North American HR Valerie Capers, the luxury electric car maker is taking certain actions starting April 13, aiming to manage costs. Facebook said it is launching new tools that will help health researchers to track and combat the spread of COVID-19 by using anonymized location data from users. The social media giant said its 'Data for Good' program is developing Disease Prevention Maps that provide details on how population movements around regions are influencing the spread of the disease. Amazon.com decided to donate 8200 laptops, worth more than $2 million, to elementary students in Seattle Public Schools (SPS) to help towards the continuous learning plan during the coronavirus (COVID-19) pandemic. SPS is the largest K-12 school system in Washington State to ensure that each student graduates ready for college, career and life.
RELATED NEWS
Follow RTT
>